Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Beta-Amyloid (1-11) Research Applications, Clinical Value, a

    2025-08-26

    Beta-Amyloid (1-11): Research Applications, Clinical Value, and Future Directions in Alzheimer’s Disease and Neurodegeneration
    Introduction (Product Overview, Mechanism of Action) [Related: g418 sulfate]
    Beta-Amyloid (1-11) is a synthetic peptide fragment corresponding to the N-terminal residues 1 through 11 of the full-length amyloid-beta (Aβ) peptide, a key pathological hallmark in Alzheimer’s disease (AD) and related neurodegenerative disorders. The Aβ peptide is generated through the sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases, resulting in peptides of varying lengths, most notably Aβ1-40 and Aβ1-42 (Selkoe & Hardy, 2016, Neuron). The N-terminal region, represented by Beta-Amyloid (1-11), is critical for understanding the initial aggregation events, immunogenicity, and interactions with cellular receptors.
    Mechanistically, Beta-Amyloid (1-11) serves as a model peptide for studying the early molecular events of amyloidogenesis, including oligomerization, aggregation, and the initiation of neurotoxic cascades. Its sequence (DAEFRHDSGYE) encompasses key residues involved in metal binding, antibody recognition, and post-translational modifications (Masters & Selkoe, 2012, Cold Spring Harb Perspect Med). This fragment is widely utilized in preclinical research to elucidate the pathophysiological mechanisms underlying AD and to develop diagnostic and therapeutic strategies targeting the amyloid cascade. [Related: ps341]
    Clinical Value and Applications [Related: mog 35-55]
    The clinical value of Beta-Amyloid (1-11) lies primarily in its utility as a research tool rather than a direct therapeutic agent. Its applications span several domains:
    1. **Biomarker Discovery and Diagnostic Development:** The N-terminal region of Aβ is a target for several diagnostic antibodies and imaging agents. Beta-Amyloid (1-11) is used to generate and validate antibodies for immunohistochemistry, ELISA, and other immunoassays, facilitating the detection of Aβ species in cerebrospinal fluid (CSF) and brain tissue (Blennow et al., 2015, Nat Rev Neurol).
    2. **Immunotherapy Research:** The peptide is instrumental in the development and preclinical testing of active and passive immunotherapies. Vaccines and monoclonal antibodies targeting the Aβ N-terminus have shown promise in reducing amyloid burden and improving cognitive outcomes in animal models (Lemere & Masliah, 2010, Neurotherapeutics).
    3. **Aggregation and Toxicity Studies:** Beta-Amyloid (1-11) is used in vitro to investigate the initial steps of Aβ aggregation, which are believed to be critical in the formation of neurotoxic oligomers and protofibrils. Understanding these processes is essential for the rational design of aggregation inhibitors (Haass & Selkoe, 2007, Nat Rev Mol Cell Biol).
    4. **Epitope Mapping and Antibody Characterization:** The peptide serves as a standard for mapping antibody epitopes and assessing the specificity and affinity of candidate therapeutic antibodies, contributing to the optimization of immunotherapeutic agents.
    Key Challenges and Pain Points Addressed
    Alzheimer’s disease remains a major unmet medical need, with current treatments offering only symptomatic relief and limited efficacy in halting disease progression. Several challenges in AD research and therapy are addressed by the use of Beta-Amyloid (1-11):
    1. **Heterogeneity of Amyloid Species:** Full-length Aβ peptides exist in multiple isoforms and aggregation states, complicating the study of their individual roles in pathology. Beta-Amyloid (1-11) provides a defined, reproducible fragment for dissecting the contributions of the N-terminal region.
    2. **Antibody Specificity:** Many therapeutic and diagnostic antibodies exhibit cross-reactivity or insufficient specificity for pathological Aβ species. Using Beta-Amyloid (1-11) in epitope mapping and antibody validation helps ensure the development of highly specific reagents (Sevigny et al., 2016, Nature).
    3. **Early Detection:** The N-terminal region is exposed in early aggregation intermediates and is a target for early diagnostic imaging. Beta-Amyloid (1-11) enables the development of assays capable of detecting pre-fibrillar Aβ species, potentially allowing for earlier intervention.
    4. **Modeling Early Aggregation Events:** The initial nucleation and oligomerization steps are poorly understood due to the complexity of full-length Aβ. The shorter Beta-Amyloid (1-11) fragment allows for detailed biophysical and structural studies of these early events.
    Literature Review
    A growing body of literature supports the utility of Beta-Amyloid (1-11) in AD research:
    1. **Antibody Development and Epitope Mapping:** - *Sevigny et al. (2016, Nature)* demonstrated the efficacy of aducanumab, a monoclonal antibody targeting aggregated Aβ, in reducing amyloid plaques. Epitope mapping using N-terminal fragments such as Beta-Amyloid (1-11) was critical in characterizing antibody specificity and affinity.
    2. **Immunotherapy Research:** - *Lemere & Masliah (2010, Neurotherapeutics)* reviewed active and passive immunization strategies targeting Aβ, highlighting the importance of N-terminal epitopes in eliciting robust immune responses with reduced risk of adverse events.
    3. **Aggregation Studies:** - *Haass & Selkoe (2007, Nat Rev Mol Cell Biol)* provided insights into the molecular mechanisms of Aβ aggregation and toxicity, emphasizing the role of N-terminal residues in modulating aggregation kinetics and neurotoxicity.
    4. **Diagnostic Development:** - *Blennow et al. (2015, Nat Rev Neurol)* discussed the development of CSF and imaging biomarkers for AD, noting the value of N-terminal Aβ fragments in improving assay sensitivity and specificity.
    5. **Structural and Biophysical Analyses:** - *Crescenzi et al. (2002, J Biol Chem)* investigated the structural properties of Aβ N-terminal fragments, including Beta-Amyloid (1-11), using NMR and other biophysical techniques, providing foundational data for understanding aggregation mechanisms.
    6. **Immunogenicity and Vaccine Design:** - *Winblad et al. (2012, Lancet Neurol)* reported on clinical trials of Aβ vaccines, where the selection of N-terminal epitopes was informed by preclinical studies using Beta-Amyloid (1-11) and related peptides.
    7. **Metal Binding and Oxidative Stress:** - *Bush et al. (2003, Trends Neurosci)* explored the role of the Aβ N-terminus in metal ion binding and oxidative stress, processes implicated in AD pathogenesis.
    Experimental Data and Results
    Experimental studies utilizing Beta-Amyloid (1-11) have yielded several key findings:
    - **Aggregation Kinetics:** Biophysical analyses have shown that Beta-Amyloid (1-11) does not form fibrils under physiological conditions but can modulate the aggregation of full-length Aβ peptides when co-incubated, suggesting a regulatory role in nucleation (Crescenzi et al., 2002, J Biol Chem).
    - **Antibody Binding:** ELISA and surface plasmon resonance (SPR) assays using Beta-Amyloid (1-11) have demonstrated high-affinity binding of several therapeutic antibodies to the N-terminal epitope, supporting its use in antibody screening and optimization (Sevigny et al., 2016, Nature).
    - **Immunogenicity:** Animal studies have shown that immunization with Beta-Amyloid (1-11) conjugated to carrier proteins elicits robust antibody responses with minimal T-cell activation, reducing the risk of autoimmune encephalitis observed with full-length Aβ vaccines (Lemere & Masliah, 2010, Neurotherapeutics).
    - **Diagnostic Assays:** Incorporation of Beta-Amyloid (1-11) into immunoassays has improved the sensitivity and specificity of CSF Aβ measurements, facilitating early diagnosis and monitoring of AD progression (Blennow et al., 2015, Nat Rev Neurol).
    - **Structural Insights:** NMR and molecular dynamics studies have revealed that the N-terminal region adopts a flexible, unstructured conformation in solution, which may facilitate interactions with metal ions and other proteins involved in AD pathology (Crescenzi et al., 2002, J Biol Chem).
    Usage Guidelines and Best Practices
    To maximize the utility of Beta-Amyloid (1-11) in research applications, the following guidelines are recommended:
    1. **Peptide Handling:** Beta-Amyloid (1-11) should be reconstituted in sterile, deionized water or appropriate buffer at concentrations recommended by the manufacturer. Aliquots should be stored at -20°C to -80°C to prevent degradation and aggregation.
    2. **Assay Development:** For immunoassays, Beta-Amyloid (1-11) can be used as a coating antigen or standard. Optimal concentrations and incubation conditions should be empir Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 21 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11580655